Valneva SE, a specialty vaccine company, today announced the signing of a new $32 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO.
Under this new one-year contract, the DoD will buy a minimum of $32 million worth of IXIARO vaccines and has the possibility to purchase additional doses during the coming twelve months. Deliveries will commence immediately.
Dipal Patel, Chief Commercial Officer of Valneva commented, “We are excited to continue our long-term relationship with the DoD. The U.S. military has trusted IXIARO for over ten years to help protect military personnel, their families, civilian government service personnel, and government contractors from this potentially deadly disease.”
IXIARO is the only JE vaccine approved by the U.S. Food and Drug Administration (FDA), having been developed through a cooperative research and development agreement with the Walter Reed Army Institute of Research. In the U.S., Valneva markets and distributes IXIARO directly to the military and private travel market.